Back
Matinas BioPharma Holdings 10K Form
Sell
22
MTNB
Matinas BioPharma Holdings
Last Price:
$0.54
Seasonality Move:
13.52%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive MTNB News And Ratings
See the #1 stock for the next 7 days that we like better than MTNB
MTNB Financial Statistics
Sales & Book Value
Annual Sales: | $1.1M |
---|---|
Cash Flow: | $-3.5M |
Price / Cash Flow: | 0 |
Annual Sales: | $3.10 |
Price / Book: | 0.18 |
Profitability
EPS (TTM): | -4.79000 |
---|---|
Net Income (TTM): | $-21.1M |
Gross Margin: | -- |
Return on Equity: | 0% |
Return on Assets: | 0% |
Matinas BioPharma Holdings Earnings Forecast
Key Matinas BioPharma Holdings Financial Ratios
-
The Research & Development expenses have been 1,321.99% of Revenue.
-
The Net Earning history of MTNB is -2,093.25% of Total Revenues.
-
Per Share Earnings over the last 11 years have been positive in 6 years.
Matinas BioPharma Holdings Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYAM |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | MTNB |
Website: | matinasbiopharma.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
MTNB Technical Analysis vs Fundamental Analysis
Sell
22
Matinas BioPharma Holdings (MTNB)
is a Sell
Is Matinas BioPharma Holdings a Buy or a Sell?
-
Matinas BioPharma Holdings stock is rated a SellThe current Matinas BioPharma Holdings [MTNB] share price is $0.55. The Score for MTNB is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.